In a possible relief for Pfizer and for abrocitinib as a JAK inhibitor, fewer patients on it than on placebo stopped therapy due to side effects. (Tracy Staton) P...

An experimental drug developed by Ionis Pharmaceuticals and Roche could offer a way forward to treat Huntington's disease, nearly three decades after researchers ...

An approval for GSK's Trelegy in asthma patients could help the company offset the continued fall of its long-time blockbuster Advair. (GlaxoSmithKline) With gen...

Kadcyla received an FDA nod for adjutant treatment of HER-2 positive breast cancer, hopefully offsetting declining sales of Roche's Herceptin. (Roche) As its onc...

Gilead's most advanced drug for non-alcoholic steatohepatitis, a fatty liver disease better known as NASH, has failed a second late-stage clinical trial, arguably co...

Drugmakers are taking longer to move a medicine from initial human testing to approval, with cumulative development times increasing from an average of about 10 year...